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Baseline Objective Inflammation by Magnetic Resonance 
Imaging as a Predictor of Therapeutic Benefit in Early 
Rheumatoid Arthritis With Poor Prognosis
Harris A. Ahmad,1 Joshua F. Baker,2 Mikkel Østergaard,3 Paul Emery,4  Patrick Durez,5 June Ye,1 
Subhashis Banerjee,1 and Philip G. Conaghan4
Objective. High magnetic resonance imaging (MRI)–detected inflammation is associated with greater progression 
and poorer outcomes in rheumatoid arthritis (RA). This analysis aimed to determine if baseline MRI inflammation was 
related to clinical response and remission in the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) study.
Methods. AVERT was a phase IIIb, randomized, controlled trial with a 12- month, double- blind treatment period 
enrolling patients with early (≤2 years’ duration), anti- citrullinated peptide–positive methotrexate (MTX)- naive RA. 
In this post hoc analysis, patients in the abatacept plus MTX (n = 114) and MTX (n = 111) arms with available MRI 
results were stratified into low and high baseline MRI inflammation groups based on previously developed cutoffs 
of synovitis and osteitis on unilateral hand–wrist contrast- enhanced MRI. Simplified Disease Activity Index (SDAI) 
remission (≤3.3), Clinical Disease Activity Index (CDAI) remission (≤2.8), Boolean remission, and Disease Activity 
Score in 28 joints using the C- reactive protein level (<2.6) were assessed.
Results. Overall, 100 of 225 patients (44.4%) had high baseline MRI inflammation. In patients with high baseline 
MRI inflammation, a significantly greater proportion achieved remission at 12 months with abatacept plus MTX 
versus MTX across SDAI (45.1% versus 16.3%; P = 0.0022), CDAI (47.1% versus 20.4%; P = 0.0065), and Boolean 
indices (39.2% versus 16.3%; P = 0.0156). In patients with low baseline MRI inflammation, remission rates were not 
significantly different with abatacept plus MTX versus MTX (SDAI: 39.7% versus 32.3%; P = 0.4961).
Conclusion. In seropositive, MTX- naive patients with early RA and presence of objectively measured high inflam-
mation by MRI, indicating poor prognosis, remission rates were higher with abatacept plus MTX treatment versus MTX.
INTRODUCTION
Rheumatoid arthritis (RA) is an immune- mediated disease, 
characterized by systemic, chronic joint inflammation that leads to 
structural damage (1). While improving the signs and symptoms 
of RA is essential, and clinical remission is a key goal of treatment, 
in order to reduce long- term disability, preventing the progression 
of structural joint damage is important (2,3).
When starting biologic therapy, the ability to identify patients 
with a greater likelihood of structural progression is important 
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to minimize disease impact through personalizing RA treatment 
approaches. Objective measures of inflammation, such as mag-
netic resonance imaging (MRI), may provide information on top of 
clinical assessments (4). MRI allows assessment of synovitis more 
accurately than clinical evaluation alone and can detect subclinical 
levels of inflammation (5,6).
MRI has the potential to be a predictive imaging biomarker, 
providing objective information that could inform treatment deci-
sions, such as when tapering of biologic therapy should be con-
sidered (7). In a 5- year follow- up study of patients with RA, MRI 
was shown to be able to identify bone erosions before these 
become evident on radiographs (8). Recent data from a second-
ary analysis of 2 randomized clinical trials suggested that it may 
be possible to stratify patients as progressors or nonprogressors 
based on their level of MRI inflammation after 24 weeks of treat-
ment and that attainment of a low MRI inflammation score may 
predict a lack of structural disease progression independently of 
attaining clinical remission (9).
Abatacept is an immunomodulator that disrupts the continu-
ous cycle of T cell activation that characterizes RA and inhibits B 
cell–derived autoantibody and proinflammatory cytokine produc-
tion (10). In the Assessing Very Early Rheumatoid arthritis Treat-
ment (AVERT) trial, a significantly greater proportion of patients 
receiving abatacept plus methotrexate (MTX) compared with MTX 
achieved Disease Activity Score in 28 joints using the C- reactive 
protein level (DAS28- CRP) remission (DAS28- CRP score <2.6) at 
12 months (P = 0.010) (1). Numerically greater reductions in sy no-
vitis, osteitis, and erosion scores from baseline were also seen 
with abatacept plus MTX compared with MTX (1).
Modern RA treatment recommendations highlight the need 
to aim for remission (11,12). A means of predicting the achieve-
ment of clinical remission would be of great value to patients 
and their treating physicians in the clinical setting. As such, the 
aim of this post hoc analysis was to determine the proportion of 
patients in each treatment arm of the AVERT study achieving clin-
ical remission over 12 months, stratified by baseline MRI- detected 
inflammation status, as an objective measure of inflammation. We 
investigated whether a greater benefit of more intensive (combi-
nation) therapy would be observed among those with high MRI 
inflammation at baseline.
PATIENTS AND METHODS
AVERT study design and procedures. AVERT was a 
phase IIIb, randomized, active- controlled trial of 24 months with 
a 12- month, double- blind treatment period (NCT01142726) and 
has been described previously (1). Briefly, eligible patients were 18 
years or older with early, active RA (persistent symptoms for ≤2 
years), DAS28- CRP ≥3.2, active clinical synovitis of ≥2 joints for 
at least 8 weeks (regardless of any current treatment), and anti– 
citrullinated peptide- 2 antibody positivity. Patients were MTX naive 
or had received MTX (≤10 mg/week) for ≤4 weeks with no MTX for 
1 month prior to enrollment (1).
During the 12- month treatment period, patients were 
stratified based on corticosteroid use at baseline (yes/no) and 
randomized 1:1:1 to receive abatacept plus MTX, abata-
cept monotherapy, or MTX. Abatacept was administered subcu-
taneously at 125 mg/week without an intravenous loading dose. 
MTX was initiated at 7.5 mg/week and titrated to 15–20 mg/
week within 6–8 weeks (≤10 mg/week permitted in patients with 
intolerance) (1). Patients with a worsening of disease requiring 
additional or amended therapy during the treatment period were 
discontinued from study participation. Only patients who were 
receiving abatacept plus MTX or MTX alone and who had avail-
able MRI data were included in the current post hoc analysis. 
The abatacept monotherapy arm was not powered for efficacy 
analyses in AVERT, and as such these patients were not included 
in the current analyses.
The AVERT study was conducted in accordance with good 
clinical practice and the Declaration of Helsinki. All patients pro-
vided written informed consent. The protocol and amendments 
were approved by the appropriate institutional review boards/
independent ethics committees at each site. Bristol  Myers Squibb 
(the sponsor) provided the study drug, designed the study, con-
ducted the study in collaboration with the principal investigators, 
collected the data, monitored the conduct of the study, and 
performed statistical analyses, including the post hoc analyses 
reported here.
MRI assessments. Contrast- enhanced 1.5T MRI of met-
acarpophalangeal joints 1–5 of the patient’s most clinically 
active hand and wrist, based on clinical assessment of synovi-
tis, was performed at baseline, 6 months, and 12 months (13). 
The same hand and wrist were imaged at each assessment. 
MRI inflammation was scored using the Outcome Measures 
in Rheumatology Rheumatoid Arthritis Magnetic Resonance 
Imaging Scoring (RAMRIS) method (14) by 2 independent cen-
tral readers who were blinded to treatment arm and using a 
randomized order of time points. The scores of both asses-
sors were averaged, and the top 5% of discrepancies for total 
change in score relative to baseline were adjudicated by con-
sensus review. Only scans from baseline and 12 months were 
used in this analysis.
SIGNIFICANCE & INNOVATIONS
• Among patients with active early rheumatoid arthri-
tis (RA), high levels of objective magnetic resonance 
imaging (MRI)–detected inflammation at baseline 
were indicative of which patients were more like-
ly to achieve clinical remission with treatment with 
abatacept plus methotrexate versus methotrexate.
• Objective identification of inflammation using MRI 
in RA may be added to the several predictive bio-
markers used to aid treatment decisions.
EARLY RA TREATMENT RESPONSE AND BASELINE MRI INFLAMMATION |      3
Post hoc analysis. Patients were stratified into “low” and 
“high” baseline MRI inflammation groups (Figure 1) based on pre-
vious analyses, which demonstrated that patients with high base-
line MRI inflammation had an increased risk of structural damage 
progression compared with those with low baseline inflammation 
(9,15). Inflammation was measured using RAMRIS scores. Low 
inflammation was defined as synovitis ≤3 or osteitis ≤3 and com-
bined ≤9 (synovitis plus osteitis [double-weighted]), and high inflam-
mation was defined as synovitis >3 and osteitis >3 or combined 
>9 (synovitis plus osteitis [double-weighted]). As in prior studies, 
osteitis was double- weighted in quantification of inflammation due 
to a greater ability to predict structural damage progression and 
greater effect on erosion development versus synovitis (9,15).
Disease activity at 12 months was compared between the 
abatacept plus MTX and MTX treatment groups within the high 
and low baseline MRI inflammation subgroups. Patients were 
assessed using the following measures: Simplified Disease  Activity 
Index (SDAI) remission (≤3.3), Clinical Disease Activity Index 
(CDAI) remission (≤2.8), Boolean remission (tender joint count ≤1, 
swollen joint count ≤1, CRP level ≤1 mg/dl, and patient’s global 
assessment of disease activity ≤1 [visual analog scale, range 0–10 
cm]), and DAS28- CRP <2.6.
Statistical analyses. Post hoc analyses were carried out 
using the intent- to- treat population, which included all patients 
who received at least 1 dose of the study drug. Only patients 
receiving abatacept plus MTX or MTX alone with available MRI 
results were included in the current post hoc analysis. Outcomes 
at 12 months were compared between treatment arms using 
statistical tests: chi- square tests for categorical variables (or 
exact method if there were <5 patients) and Student’s t- tests for 
numerical variables.
RESULTS
Patients. Of the 351 patients enrolled and randomized to 
treatment in the AVERT study, 119 were randomized to receive 
abatacept plus MTX and 116 to receive MTX. Of these 235 
patients, 225 (95.7%) had baseline MRI data available: 114 of 119 
patients (95.8%) in the abatacept plus MTX arm and 111 of 116 
(95.7%) in the MTX arm. Baseline MRI scans were not available for 
10 of 235 patients (4.3%).
Baseline characteristics of the AVERT study have been 
reported previously (1). Briefly, patients had a mean RA symptom 
duration of 0.58 years in the abatacept plus MTX group and 0.50 
years in the MTX group. The patient population had highly inflam-
matory disease: mean tender joint count 14.0 and 12.8, swollen 
joint count 11.2 and 10.7, CRP level 18.1 mg/liter and 17.3 mg/
liter, and mean DAS28- CRP 5.5 and 5.3 in the abatacept plus 
MTX and MTX groups, respectively.
At baseline, 125 of 225 patients (55.6%) were classified as 
having low MRI inflammation, and 100 of 225 (44.4%) as hav-
ing high MRI inflammation (Table 1). A total of 51 of 114 patients 
Figure  1. Contrast- enhanced 1.5T magnetic resonance image 
(MRI) of metacarpophalangeal joints 1–5 and wrist with low (A) 
and high (B) MRI- detected inflammation. Low MRI inflammation: 
synovitis ≤3 or osteitis ≤3 and combined ≤9 (synovitis plus osteitis 
[double-weighted]). High MRI inflammation: synovitis >3 and osteitis 
>3 or combined >9 (synovitis plus osteitis [double-weighted]).
Synovitis Osteitis Combined
2 0 2
Synovitis Osteitis Combined
8 7 22
A B
Table 1. Baseline magnetic resonance imaging (MRI) inflammation and disease activity measures by baseline MRI 
inflammation status and by treatment group*
Low MRI inflammation High MRI inflammation
Abatacept plus 
MTX 
(n = 63)
MTX 
(n = 62)
Abatacept plus 
MTX 
(n = 51)
MTX 
(n = 49)
MRI- detected inflammation measures
Synovitis 2.6 ± 2.0 3.1 ± 2.4 9.2 ± 3.6 9.3 ± 3.6
Osteitis 0.3 ± 0.6 0.2 ± 0.5 10.0 ± 9.7 10.7 ± 9.8
Combined† 3.1 ± 2.4 3.5 ± 2.7 29.3 ± 21.3 30.7 ± 21.3
Disease activity measures
SDAI 39.9 ± 17.4 43.5 ± 24.6 76.9 ± 44.9 61.1 ± 35.2
CDAI 34.0 ± 14.7 32.1 ± 15.0 43.4 ± 16.2 37.7 ± 18.1
DAS28- CRP 5.1 ± 1.1 5.0 ± 1.3 6.2 ± 1.2 5.6 ± 1.4
* Values are the mean ± SD. MTX = methotrexate; SDAI = Simplified Disease Activity Index; CDAI = Clinical Disease Activity 
Index; DAS28- CRP = Disease Activity Score in 28 joints using the C- reactive protein level. 
† Osteitis double weighted. 
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(44.7%) in the abatacept plus MTX arm and 49 of 111 patients 
(44.1%) in the MTX arm were classified as having high MRI inflam-
mation at baseline.
Post hoc analyses. Baseline. Among patients with high 
MRI inflammation at baseline, the mean ± SD combined inflam-
mation measure was 29.3 ± 21.3 in the abatacept plus MTX 
group and 30.7 ± 21.3 in the MTX group. Among patients with 
low MRI inflammation at baseline, the mean ± SD combined in-
flammation measure was 3.1 ± 2.4 for patients in the abatacept 
plus MTX group and 3.5 ± 2.7 for patients in the MTX group. All 
disease activity scores (SDAI, CDAI, and DAS28- CRP) were nu-
merically higher in patients with high MRI inflammation at base-
line versus those with low inflammation (Table 1).
12 months. Among patients with high MRI inflammation 
at baseline, the proportion of patients that achieved remis-
sion was significantly greater in the abatacept plus MTX group 
than in the MTX group for SDAI (45.1% versus 16.3%; P = 
0.0022), CDAI (47.1% versus 20.4%; P = 0.0065), and Boolean 
(39.2% versus 16.3%; P = 0.0156) indices. Numerical differ-
ences in the proportions of patients achieving a DAS28- CRP 
score of <2.6 were seen (60.8% versus 40.8%; P = 0.0667) 
(Figure  2). In those with low MRI inflammation at baseline, 
the proportion who achieved remission at month 12 based 
on any of the clinical remission criteria (SDAI, CDAI, Boolean, 
or DAS28- CRP) was numerically, but not significantly, higher 
in the abatacept plus MTX group than in the MTX group 
(Figure 2).
Figure  2. Efficacy outcomes at 12 months by baseline magnetic resonance imaging (MRI) inflammation status and by treatment 
group (post hoc analyses). Proportion of patients with Simplified Disease Activity Index (SDAI) score ≤3.3 (A), Clinical Disease Activity 
Index (CDAI) score ≤2.8 (B), Boolean remission (tender joint count ≤1, swollen joint count ≤1, C- reactive protein [CRP] level ≤1 mg/dl, 
and patient global assessment of disease activity ≤1) (C), and Disease Activity Score in 28 joints using the CRP level (DAS28- CRP) <2.6 (D). For 
low MRI inflammation at baseline, n = 63 for abatacept plus methotrexate (MTX), and n = 62 for MTX. For high MRI inflammation at baseline, 
n = 51 for abatacept plus MTX, and n = 49 for MTX. Normal approximations were used if the number of patients with SDAI score ≤3.3, CDAI 
score ≤2.8, Boolean remission, or DAS28- CRP score <2.6 was ≥5, otherwise an exact method was used. * = P < 0.05 for abatacept plus MTX 
versus MTX; SDAI P = 0.0022, CDAI P = 0.0065, Boolean remission P = 0.0156.
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DISCUSSION
In this post hoc analysis of the AVERT study, patients with 
early RA and a high MRI inflammation status at baseline who 
were treated with abatacept plus MTX were statistically more 
likely to achieve clinical remission than those treated with MTX. 
In contrast, among those with low MRI inflammation at baseline, 
remission rates were numerically, but not significantly, higher in the 
abatacept plus MTX and MTX groups, and no statistically signifi-
cant differences were observed for any outcome measure.
Abatacept in combination with MTX has been shown to be 
significantly more effective in the treatment of RA than MTX, with 
a good safety and tolerability profile (1). To our knowledge, this is 
the first analysis to examine the effects of abatacept treatment 
in combination with MTX in a patient cohort stratified by a poor 
prognostic factor based on objective baseline MRI inflamma-
tion status. Our findings demonstrated that abatacept plus MTX 
was more effective than MTX at inducing remission in patients with 
RA irrespective of baseline levels of MRI inflammation, but that 
the benefit seen with combination therapy was greater in patients 
with higher baseline inflammation than in those with lower base-
line inflammation. Notably, greater differences in the proportions of 
patients achieving remission with abatacept plus MTX versus MTX 
were seen in the group with high MRI inflammation at baseline, a 
feature indicative of poor prognosis. Thus, we speculate that pres-
ence of high MRI inflammation and potentially other poor prog-
nostic factors could be used to risk- stratify patients and determine 
who might derive the greatest benefit from initiation of abatacept 
therapy. However, caution must be exercised during this stratifi-
cation, and MRI inflammation must be considered in the context 
of other biomarkers to prevent suboptimal treatment of patients 
considered to have a better prognosis (patients with low MRI 
inflammation). Although seropositive patients with high objective 
disease activity at baseline are at a greater risk for poor outcomes 
than those without these factors, patients without such factors still 
endure a prognosis that is life altering. Thus, patients considered 
to have a better prognosis should still be treated according to the 
current treatment guidelines, and objective assessment of inflam-
mation in these seronegative patients may enable further patient 
stratification and the selection of appropriate patients for therapy 
escalation.
The current findings are important because biomarkers, such 
as MRI, that may help to determine which individuals are most 
likely to benefit from a particular therapy are of great interest. How-
ever, the high cost of MRI and its accessibility in daily clinical care 
are currently limiting factors in its adoption for use in routine clinical 
practice. The cost of MRI should be considered in the context 
of the costs avoided by preventing prescription of a specific bio-
logic therapy to those patients who would be less likely to benefit 
from them, and furthermore by potentially preventing the conse-
quences of inadequate disease control. The current study used 
a clinical trial cohort and MRI to demonstrate the potential utility 
of objectively measuring inflammation to identify patients who are 
likely to derive benefit from a particular therapy. Translation into 
clinical practice will depend on a variety of factors: the cost of 
MRI in the context of the costs that would be avoided by prevent-
ing prescription of a specific biologic therapy to patients less likely 
to benefit from it (including the management of adverse events); 
assessment of the risks and longer- term benefits associated with 
treating patients with high inflammation with early  intensive  therapy; 
advances in technologies allowing for better routine quantification 
of inflammation; and the increasing use of modern imaging tech-
nologies more suited to routine use than MRI. The current study is 
a first step in understanding how MRI might have value in helping 
to identify these patients. More studies are still required in other 
populations with RA and varying clinical disease activity.
The prognostic and predictive value of MRI has been 
demonstrated in other contexts. For example, in a study of 143 
patients with RA in clinical remission while receiving biologic 
disease- modifying antirheumatic drugs (bDMARDs), MRI was an 
independent predictor of successful tapering. The study demon-
strated that the use of >1 previous bDMARD, male sex, and low 
baseline MRI combined inflammation or combined damage score 
were all independent predictors of successful tapering (7).
The limitations of the current study should be considered. 
These were post hoc analyses, and the AVERT study was not 
designed specifically to answer the questions posed, nor was it 
powered to investigate these questions. In particular, the aba-
tacept monotherapy arm was not powered for efficacy analyses 
in AVERT, and as such these patients were not included in the 
current analyses. Although this study provides a proof of con-
cept, based on the use of MTX and a biologic agent, an approach 
employing the treat- to- target strategy with concomitant tem-
porary glucocorticoids would also provide valuable insights into 
appropriate treatment regimens. While the inclusion of patients 
with only a narrow range of disease activity scores (DAS28- CRP 
≥3.2) allowed MRI inflammation to be assessed independently of 
disease activity, future studies with broader clinical disease activity 
inclusion criteria would be of value. In addition, clinical remission 
was only assessed at a single time point. It is important to consider 
that only the hand and wrist were imaged for each patient rather 
than multiple joints, and misclassification of MRI activity may occur 
to some degree in individuals with oligoarticular and asymmetrical 
disease; however, all MRI predictive validity work has been con-
ducted using the single- hand scanning as performed in this study. 
Further validation of the threshold for high versus low MRI inflam-
mation is required; in particular, analyses in a long- term cohort are 
needed to determine the best weight of osteitis versus synovitis 
to gauge severity of joint inflammation. Finally, tenosynovitis was 
not assessed in this study and may add to the imaging evaluation.
In conclusion, these post hoc analyses of the AVERT study 
showed that patients with early RA and a high level of MRI inflam-
mation at baseline were more likely to achieve clinical remission 
with abatacept plus MTX compared with MTX. MRI as a measure 
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of inflammation can provide added value as an objective assess-
ment of disease to influence clinical decision making and guide 
the more precise use of therapies to treat RA.
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